- Home
- ELEV vs OCX Comparison
ELEV vs OCX Comparison
Compare ELEV & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- OCX
- Stock Information
- Founded
- ELEV 2019
- OCX 2009
- Country
- ELEV United States
- OCX United States
- Employees
- ELEV N/A
- OCX N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ELEV Health Care
- OCX Health Care
- Exchange
- ELEV Nasdaq
- OCX Nasdaq
- Market Cap
- ELEV 34.0M
- OCX 38.7M
- IPO Year
- ELEV 2021
- OCX N/A
- Fundamental
- Price
- ELEV $0.61
- OCX $2.66
- Analyst Decision
- ELEV Strong Buy
- OCX Buy
- Analyst Count
- ELEV 5
- OCX 3
- Target Price
- ELEV $7.80
- OCX $4.42
- AVG Volume (30 Days)
- ELEV 673.9K
- OCX 64.9K
- Earning Date
- ELEV 11-06-2024
- OCX 11-12-2024
- Dividend Yield
- ELEV N/A
- OCX N/A
- EPS Growth
- ELEV N/A
- OCX N/A
- EPS
- ELEV N/A
- OCX N/A
- Revenue
- ELEV N/A
- OCX $709,000.00
- Revenue This Year
- ELEV N/A
- OCX N/A
- Revenue Next Year
- ELEV N/A
- OCX $167.93
- P/E Ratio
- ELEV N/A
- OCX N/A
- Revenue Growth
- ELEV N/A
- OCX N/A
- 52 Week Low
- ELEV $0.44
- OCX $2.29
- 52 Week High
- ELEV $5.83
- OCX $4.31
- Technical
- Relative Strength Index (RSI)
- ELEV 51.53
- OCX 39.09
- Support Level
- ELEV $0.52
- OCX $2.50
- Resistance Level
- ELEV $0.70
- OCX $3.04
- Average True Range (ATR)
- ELEV 0.06
- OCX 0.17
- MACD
- ELEV 0.00
- OCX -0.03
- Stochastic Oscillator
- ELEV 41.81
- OCX 29.96
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.